All In Biotech

Drug Trial Radar · NCT06440746

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase 2/3 Study of Efficacy and Safety of Olokizumab in Subjects With Progressive Fibrosing Interstitial Lung Diseases

Last checked: Nov 20, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Aug 23, 2023

Primary completion

Apr 9, 2027

Study completion Dec 25, 2028

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
R-Pharm; Exacte Labs LLC; Data Management 365; Keystat, LLC
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).

Conditions

  • Lung Diseases, Interstitial

Interventions

  • Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)Drug

    Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.

  • SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mLDrug

    Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of forced vital capacity (FVC)Time frame: 48 weeks

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Regional Clinical Hospital Regional state budgetary healthcare institution

    Barnaul, Russia · Recruiting

  • Regional Clinic Hospital№3

    Chelyabinsk, Russia · Recruiting

  • Chelyabinsk Regional Clinical Hospital

    Chelyabinsk, Russia · Recruiting

  • State budgetary healthcare institution of the Leningrad region "Gatchina Clinical Interdistrict Hospital"

    Gatchina, Russia · Recruiting

  • LLC" Medsi-Izhevsk"

    Izhevsk, Russia · Recruiting

  • LLC "Scientific Research Medical Complex "Your Health"

    Kazan', Russia · Recruiting

  • Kuzbass Clinical Hospital Emergency Medical Care named after Podgorbunsky M.A

    Kemerovo, Russia · Recruiting

  • State Budgetary Healthcare Institution Research Institute-Karpaty Clinical Hospital No. 1 named after prof. S.V. Ochapovsky

    Krasnodar, Russia · Recruiting

  • City Clinical Hospital named after Davydovsky I.V.

    Moscow, Russia · Recruiting

  • GBUZ Moscow Clinical Scientific Center named after Loginov MHD

    Moscow, Russia · Recruiting

  • Scientific Research Institute of Reumatology named after Nasonova V.A

    Moscow, Russia · Recruiting

  • Moscow City Polyclinic №52

    Moscow, Russia · Recruiting

  • Clinical Hospital №4 of Sechenov University

    Moscow, Russia · Recruiting

  • Clinical Hospital №3 of Sechenov University

    Moscow, Russia · Recruiting

  • State Budgetary Healthcare Institution of Moscow City "City Clinical Hospital №52" of the Moscow City Health Department", Consultative and diagnostic department №2

    Moscow, Russia · Recruiting

  • State Budgetary Healthcare Institution of Moscow City "City Clinical Hospital №52" of the Moscow City Health Department"

    Moscow, Russia · Recruiting

  • FSBEI HE "Russian University of Medicine", MoH of Russia

    Moscow, Russia · Recruiting

  • Moscow Regional Research and Clinical Institute "MONIKI"

    Moscow, Russia · Recruiting

  • Federal Research Center Institute of Cytologyand Genetics,Siberian Branch of Russian Academy of Sciences

    Novosibirsk, Russia · Recruiting

  • Republican Hospital named after V.A. Baranov

    Petrozavodsk, Russia · Recruiting

  • Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation

    Saint Petersburg, Russia · Recruiting

  • LLC"Energy of Health"

    Saint Petersburg, Russia · Recruiting

  • Medical Center "Interleukin"

    Saint Petersburg, Russia · Recruiting

  • City Multidisciplinary Hospital №2-Expert Center in the field of Pulmonology

    Saint Petersburg, Russia · Recruiting

  • LLC"Kurator"

    Saint Petersburg, Russia · Recruiting

  • State Healthcare Institution "Regional Clinical Hospital"

    Saratov, Russia · Recruiting

  • Regional state budgetary healthcare institution "Clinical Hospital No. 1"

    Smolensk, Russia · Recruiting

  • Regional State Budgetary Healthcare Institution "Medical and Sanitary Unit No. 2

    Tomsk, Russia · Recruiting

  • Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation

    Ufa, Russia · Recruiting

  • State Budgetary Healthcare Institution of the Vladimir Region "Regional Clinical Hospital"

    Vladimir, Russia · Recruiting

  • Budgetary healthcare institution of the Voronezh region "Voronezh Regional Clinical Hospital No1"

    Voronezh, Russia · Recruiting

  • Clinical Hospital of Emergency Medical Care named after Solovyov N.V

    Yaroslavl, Russia · Recruiting

  • Ural research Institute of Phthisiopulmonology

    Yekaterinburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.